Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Hematological Problems in Pediatric Intensive Care
3.514
Zitationen
4
Autoren
2013
Jahr
Abstract
Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) has been used in children with von Willebrand disease (VWD) and Hemophilia A for almost 35 years. This treatment has substantially lowered the number of children exposed to human plasma derived products, with a good safety profile, and at very low cost. The response to DDAVP has been shown to be associated with age, baseline factor level, and genetic mutations. A DDAVP challenge test is recommended. DDAVP has also been used to prevent and treat bleeding episodes in children with platelet function defects and other disorders associated with bleeding tendency.
Ähnliche Arbeiten
Mutation in blood coagulation factor V associated with resistance to activated protein C
1994 · 3.832 Zit.
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
1993 · 1.984 Zit.
Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
2007 · 1.918 Zit.
Guidelines for the management of hemophilia
2012 · 1.910 Zit.
Hemostasis and Thrombosis: Basic Principles and Clinical Practice.
1988 · 1.857 Zit.